The prognostic effect of the systemic immune-inflammation index on overall survival of periampullary cancer

References

• de Jong EJM, van der Geest LG, Besselink MG, et al. Treatment and overall survival of four types of non-metastatic periampullary cancer: nationwide population-based cohort study. HPB (Oxford). 2022;24(9):1433–1442. doi:10.1016/j.hpb.2022.01.009.
   PubMed Web of Science ®Google Scholar
• Winter JB, Abrams RA, Posey JA, et al. Cancer of the pancreas. In: deVita. VT, Rosenberg. SA., ed. Cancer principles & practice of oncology. 11th ed. USA: Wolters Kluwer 2019.
   Google Scholar
• Poruk KG, Cl W, Jl C. Pancreatic and periampullary cancer. In: Yeo CJ, ed. Shackelford’s surgery of the alimentary tract. 8th ed. Philadelphia: Elsevier 2019:1136–1148.
   Google Scholar
• Buscail E, Maulat C, Muscari F, et al. Liquid biopsy approach for pancreatic ductal adenocarcinoma. Cancers (Basel). 2019;11(6):852. doi:10.3390/cancers11060852.
   Web of Science ®Google Scholar
• Tse F, Barkun JS, Romagnuolo J, et al. Nonoperative imaging techniques in suspected biliary tract obstruction. HPB (Oxford). 2006;8(6):409–425. doi:10.1080/13651820600746867.
   PubMedGoogle Scholar
• Rizzo A, Brandi G. First-line chemotherapy in advanced biliary tract cancer ten years after the ABC-02 trial: "and yet it moves!. Cancer Treat Res Commun. 2021;27:100335. doi:10.1016/j.ctarc.2021.100335.
   PubMedGoogle Scholar
• Rizzo A, Brandi G. BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care. Expert Rev Gastroenterol Hepatol. 2021;15(5):483–485. doi:10.1080/17474124.2021.1864325.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Dadduzio V, Lombardi L, et al. Ampullary carcinoma: an overview of a rare entity and discussion of current and future therapeutic challenges. Curr Oncol. 2021;8(5):3393–3402. doi:10.3390/curroncol28050293.
   Web of Science ®Google Scholar
• Shui Y, Li M, Su J, et al. Prognostic and clinicopathological significance of systemic immune-inflammation index in pancreatic cancer: a meta-analysis of 2,365 patients. Aging (Albany NY). 2021;13(16):20585–20597. doi:10.18632/aging.203449.
   PubMedGoogle Scholar
• Li X, Lin H, Ouyang R, et al. Prognostic significance of the systemic immune-inflammation index in pancreatic carcinoma patients: a meta-analysis. Biosci Rep. 2021;41(8):BSR20204401. doi:10.1042/BSR20204401.
   Web of Science ®Google Scholar
• Aziz MH, Sideras K, Aziz NA, et al. The systemic-immune-inflammation index independently predicts survival and recurrence in resectable pancreatic cancer and its prognostic value depends on bilirubin levels: a retrospective multicenter cohort study. Ann Surg. 2019;70(1):139–146. doi:10.1097/SLA.0000000000002660.
   Web of Science ®Google Scholar
• Bittoni A, Pecci F, Mentrasti G, et al. Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer. Ann Transl Med. 2021;9(3):251. doi:10.21037/atm-20-3499.
   PubMed Web of Science ®Google Scholar
• Jomrich G, Gruber ES, Winkler D, et al. Systemic Immune-Inflammation index (SII) predicts poor survival in pancreatic cancer patients undergoing resection. J Gastrointest Surg. 2020;24(3):610–618. doi:10.1007/s11605-019-04187-z.
   PubMed Web of Science ®Google Scholar
• Shang J, Han X, Zha H, et al. Systemic Immune-Inflammation index and changes of Neutrophil-Lymphocyte ratio as prognostic biomarkers for patients with pancreatic cancer treated with immune checkpoint blockade. Front Oncol. 2021;11:585271. doi:10.3389/fonc.2021.585271.
   PubMed Web of Science ®Google Scholar
• Terasaki F, Sugiura T, Okamura Y, et al. Systemic immune-inflammation index as a prognostic marker for distal cholangiocarcinoma. Surg Today. 2021;51(10):1602–1609. doi:10.1007/s00595-021-02312-7.
   PubMed Web of Science ®Google Scholar
• Zhang K, Hua YQ, Wang D, et al. Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer. J Transl Med. 2019;17(1):30. doi:10.1186/s12967-019-1782-x.
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Ashida R, Sugiura T, et al. Prognostic impact of indicators of systemic inflammation and the nutritional status of patients with resected carcinoma of the ampulla of vater: a Single-Center retrospective study. World J Surg. 2022;46(1):246–258. doi:10.1007/s00268-021-06346-3.
   PubMed Web of Science ®Google Scholar
• Nehring SM, Goyal A, Patel BC. C reactive protein. StatPearls. Treasure Island (FL) 2022.
   Google Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to virchow? Lancet. 2001;357(9255):539–545. doi:10.1016/S0140-6736(00)04046-0.
   PubMed Web of Science ®Google Scholar
• Candido J, Hagemann T. Cancer-related inflammation. J Clin Immunol. 2013;33(Suppl 1):S79–S84. doi:10.1007/s10875-012-9847-0.
   PubMed Web of Science ®Google Scholar
• Elinav E, Nowarski R, Thaiss CA, et al. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13(11):759–771. doi:10.1038/nrc3611.
   PubMed Web of Science ®Google Scholar
• Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005;5(4):263–274. doi:10.1038/nrc1586.
   PubMed Web of Science ®Google Scholar
• De Larco JE, Wuertz BR, Furcht LT. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin Cancer Res. 2004;10(15):4895–4900. doi:10.1158/1078-0432.CCR-03-0760.
   PubMed Web of Science ®Google Scholar
• Kusumanto YH, Dam WA, Hospers GA, et al. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis. 2003;6(4):283–287. doi:10.1023/B:.AGEN.0000029415.62384.ba
   PubMedGoogle Scholar
• Di Mitri D, Toso A, Chen JJ, et al. Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer. Nature. 2014;515(7525):134–137. doi:10.1038/nature13638.
   PubMed Web of Science ®Google Scholar
• Meikle CK, Kelly CA, Garg P, et al. Cancer and thrombosis: the platelet perspective. Front Cell Dev Biol. 2016;4:147. doi:10.3389/fcell.2016.00147.
   PubMed Web of Science ®Google Scholar
• Chiba T, Ohtani H, Mizoi T, et al. Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis. Br J Cancer. 2004;91(9):1711–1717. doi:10.1038/sj.bjc.6602201.
   PubMed Web of Science ®Google Scholar
• Chen JH, Zhai ET, Yuan YJ, et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017;23(34):6261–6272. doi:10.3748/wjg.v23.i34.6261.
   PubMed Web of Science ®Google Scholar
• Murthy P, Zenati MS, Al Abbas AI, et al. Prognostic value of the systemic Immune-Inflammation index (SII) after neoadjuvant therapy for patients with resected pancreatic cancer. Ann Surg Oncol. 2020;27(3):898–906. doi:10.1245/s10434-019-08094-0.
   PubMed Web of Science ®Google Scholar
• Fest J, Ruiter R, Mulder M, et al. The systemic immune-inflammation index is associated with an increased risk of incident cancer-A population-based cohort study. Int J Cancer. 2020;46(3):692–698. doi:10.1002/ijc.32303.
   Web of Science ®Google Scholar
• Fei Y, Wang X, Zhang H, et al. Reference intervals of systemic immune-inflammation index, neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, mean platelet volume to platelet ratio, mean platelet volume and red blood cell distribution width-standard deviation in healthy han adults in wuhan region in Central China. Scand J Clin Lab Invest. 2020;80(6):500–507. doi:10.1080/00365513.2020.1793220.
   PubMed Web of Science ®Google Scholar
• Luo H, He L, Zhang G, et al. Normal reference intervals of Neutrophil-To-Lymphocyte ratio, Platelet-To-Lymphocyte ratio, Lymphocyte-To-Monocyte ratio, and systemic immune inflammation index in healthy adults: a large Multi-Center study from Western China. Clin Lab. 2019;65(3):255–265. doi:10.7754/Clin.Lab.2018.180715.
   Web of Science ®Google Scholar
• Stevens L, Pathak S, Nunes QM, et al. Prognostic significance of pre-operative C-reactive protein and the neutrophil-lymphocyte ratio in resectable pancreatic cancer: a systematic review. HPB (Oxford). 2015;17(4):285–291. doi:10.1111/hpb.12355.
   PubMed Web of Science ®Google Scholar
• Merlo I, Ardiles V, Sanchez-Claria R, et al. Prognostic factors in resected pancreatic ductal adenocarcinoma: is Neutrophil-Lymphocyte ratio a useful marker? J Gastrointest Cancer. 2022. doi:10.1007/s12029-022-00839-7.
   PubMed Web of Science ®Google Scholar
• Zhou W, Kuang T, Han X, et al. Prognostic role of lymphocyte-to-monocyte ratio in pancreatic neuroendocrine neoplasms. Endocr Connect. 2020;9(4):289–298. doi:10.1530/EC-19-0541.
   PubMed Web of Science ®Google Scholar
• Schlanger D, Popa C, Pașca S, et al. The role of systemic immuno-inflammatory factors in resectable pancreatic adenocarcinoma: a cohort retrospective study. World J Surg Oncol. 2022;20(1):144. doi:10.1186/s12957-022-02606-1.
   PubMed Web of Science ®Google Scholar
• Fan L, Wang R, Chi C, et al. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients. Prostate. 2018;78(4):250–256. doi:10.1002/pros.23465.
   PubMed Web of Science ®Google Scholar